Oxyntomodulin for Preventing or Treating Excess Weight

• US 20110034374A1
• Filed: 01/29/2010
• Published: 02/10/2011
• Est. Priority Date: 09/07/2001
• Status: Abandoned Application

• Current Assignee: Imperial Innovations Limited (Imperial College London)
• Original Assignee: Imperial Innovations Limited (Imperial College London)
• Inventors: Small, Caroline Jane, Ghatei, Mohammad Ali, Bloom, Stephen Robert, Dakin, Catherine Louise
• Application Number:
  US12/696,493
• Publication Number:
  US 20110034374A1
• Time in Patent Office: Days
• US Class Current: 514/5.3
• CPC Class Codes: A61K 38/22 Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35
• CPC Class Codes: A61K 38/26 Glucagons
• CPC Class Codes: A61K 47/02 Inorganic compounds
• CPC Class Codes: A61K 47/543 Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
• CPC Class Codes: A61K 47/60 the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/0053 Mouth and digestive tract, i.e. intraoral and peroral administration rectal administration A61K9/0031
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents

Abstract

Compositions and methods for use in the prevention or treatment of excess weight in a mammal have been developed. The compositions comprise oxyntomodulin which is shown to reduce food intake.

Claims

1. A composition comprising oxyntomodulin, for use in the prevention or treatment of excess weight in a mammal.

2. A composition comprising oxyntomodulin, for use as claimed in claim 1, wherein the excess weight is obesity.

3. A composition comprising oxyntomodulin, for use as claimed in claim 1 or claim 2, in combination with a pharmaceutically acceptable excipient.

4. A composition comprising oxyntomodulin, for use as claimed in any one of claims 1 to 3, in liquid, solid or semi-solid form.

5. A composition comprising oxyntomodulin, for use as claimed in any one of claims 1 to 4, wherein the mammal is a human.

6. A method for the prevention or treatment of excess weight in a mammal, the method comprising administering a composition comprising oxyntomodulin to a mammal.

7. A method, as claimed in claim 6, wherein the excess weight is obesity.

9. A method, as claimed in any one of claims 6 to 8, wherein the composition comprises oxyntomodulin and a pharmaceutically acceptable excipient or carrier.

10. A method, as claimed in any of claims 6 to 9, wherein the weight loss is a result of reduced food intake.

8. A method for cosmetic weight loss in a mammal, the method comprising administering a composition comprising oxyntomodulin to a mammal.

11. Use of oxyntomodulin, in the manufacture of a medicament for the prevention or treatment of excess weight.

12. The use of oxyntomodulin to identify an agent which inhibits food intake in a mammal.

13. The use, as claimed in claim 12, which is of the functional and/or structural characteristics of oxyntomodulin.

14. The use, as claimed in claim 12 or claim 13, which is of an electronically generated model of oxyntomodulin.

15. The use, as claimed in any one of claims 12 to 14, wherein the characteristic of oxyntomodulin is its primary, secondary, tertiary structure pharmacophore and/or X-ray crystal structure.

16. A composition comprising oxyntomodulin, for use in the prevention or treatment of excess weight in a mammal as hereinbefore described in the examples.

17. A method for the prevention or treatment of excess weight in a mammal, the method as described with reference to the examples.